VI
VivoSim Labs, Inc.
VIVS · NASDAQ
$0.23 -12.56% (-$0.03)
1M -22.26%
Market Cap $583.1K
P/E Ratio -
Div. Yield -
ROE 612.23%
Bulios Fair Price
$0.27
18.9% upside
Current Price
$0.23
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VIVS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
33 /100
Expensive P/S 5.21x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 29.26%
EPS growth N/A
FCF growth N/A
Profitability
0 /100
Weak Gross margin 134.82%
Net margin 11,016.10%
Op. margin 10,117.00%
Quality
0 /100
Poor ROIC 499.37%
ROE 612.23%
ROA 320.72%
Debt
36 /100
Moderate Current ratio 1.70x
Int. coverage -1,026.75x
Debt/Equity N/A
Stability
10 /100
Unstable Beta 1.45x
Rev. volatility 51.66%
EPS volatility 159.89%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VIVS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Keith Murphy
Employees
15
Headquarters
San Diego
Upcoming events
05 NOV
Earnings
Upcoming earnings report